Abstract: A telescopic device includes a first U-shaped connector with a plurality sets of adjustment slots defined in two sides thereof and arranged along an adjustment direction; a second U-shaped connector defining first through holes in two sides thereof, the second U-shaped connector being inserted into the first U-shaped connector with U-shaped openings thereof opposite to each other to define an accommodating space; a first spring located in the accommodating space and abutting against the first and second U-shaped connectors, respectively; an elastic pin with two ends thereof extending through the first through holes and engaging into one of the plurality sets of adjustment slots; and an initial fixing pin being detachably connected to the first and second U-shaped connectors. A telescopic annular tunnel steel arch includes an upper arch, two lower arches and two telescopic devices connecting two ends of the upper arch to the two lower arches, respectively.

Abstract: Improved methods for treating neoplastic diseases such as cancer are provided by using muteins of human tumor necrosis factor-alpha (TNF-?). Compared to wild-type human TNF-? these therapeutic TNF muteins have higher specific anti-tumor activity, but with much reduced systemic toxicity and milder side effects such chills and fever. In addition, potentially synergistic, novel combinations of the inventive TNF-? muteins with other anti-neoplastic agents are provided for effectively treating patients having particular types of cancer or malignancy or at particular stages of cancer development, and for mitigating resistance of the patients to treatment of non-TNF antineoplastic agents.

Abstract: Improved methods for treating neoplastic diseases such as cancer are provided by using muteins of human tumor necrosis factor-alpha (TNF-&agr;). Compared to wild-type human TNF-&agr; these therapeutic TNF muteins have higher specific anti-tumor activity, but with much reduced systemic toxicity and milder side effects such chills and fever. In addition, potentially synergistic, novel combinations of the inventive TNF-&agr; muteins with other anti-neoplastic agents are provided for effectively treating patients having particular types of cancer or malignancy or at particular stages of cancer development.